



UNITED ST. S DEPARTMENT OF COMMERCE Patent and Trademark Office

Address: COMMISSIONER OF PATENTS AND TRADEMARKS Washington, D.C. 20231 mon

	APPLICATION NO.	FILING DATE	FIRST NAME	D INVENTOR	ATT	TORNEY DOCKET NO.
	09/658,659	09/08/00	STANTON		V	
Г	-			コ	EXAMINER	
•			HM12/100:	l.		
	ANITA L. MEIKLEJOHN, PH.D.				<u>CHAKRARARTI A</u>	
	FISH & RIC!	HARDSON P.O	e a		ART UNIT	PAPER NUMBER
	225 FRANLIN STREET					
	BOSTON MA	02110-2804			1655 Date Mailed:	12

Please find below and/or attached an Office communication concerning this application or proceeding.

Commissioner of Patents and Trademarks

10/01/01





UNITED STATES DEPARTMENT OF COMMERCE

Trademark Office ONER OF PATENTS AND TRADEMARKS

Washington, D.C. 20231

		0.01,00,100	
		FIRST	NAMED APPLICANT
SERIAL NUMBER	FILING DATE		ATTORNEY DOCKET NO.
09/658,659	9/8/00	Stanton	030586.0017.CIP3
*			

MINER
PAPER NUMBER
12

DATE MAILED:

Please find below a communication from the EXAMINER in charge of this application

The communication filed on September 20, 2001 is non-responsive to the prior Office action because it fails to comply with the Sequence Rules. Specifically, no CRF was received by the Scientific and Technical Information Center, though the paper copy of the sequences was filed. Since the response appears to be bona fide, but through an apparent oversight or inadvertence failed to provide a complete response, applicant is required to complete the response within a TIME LIMIT of ONE MONTH from the date of this letter or within the time remaining in the response period of the last Office action, whichever is longer. Applicant may elect to either extend the period for response set in the last office action up to a maximum of SIX MONTHS or to extend from this ONE MONTH limit under 37 CFR 1.136 (a) or (b) up to SIX MONTHS from the mailing date of this letter.

> Supervisory Patent Examiner Technology Center 1600

> > 9/78/01

Application No.: 09/658,659

NOTICE TO COMPLY WITH REQUIREMENTS FOR PATENT APPLICATIONS CONTAINING NUCLEOTIDE SEQUENCE AND/OR AMINO ACID SEQUENCE DISCLOSURES

Applicant must file the items indicated below within the time period set the Office action to which the Notice is attached to avoid abandonment under 35 U.S.C. § 133 (extensions of time may be obtained under the provisions of 37 CFR 1.136(a)).

comply	eleotide and/or amino acid sequence disclosure contained in this application does not with the requirements for such a disclosure as set forth in 37 C.F.R. 1.821 - 1.825 for the g reason(s):
	1. This application clearly fails to comply with the requirements of 37 C.F.R. 1.821-1.825. Applicant's attention is directed to the final rulemaking notice published at 55 FR 18230 (May 1, 1990), and 1114 OG 29 (May 15, 1990). If the effective filing date is on or after July 1, 1998, see the final rulemaking notice published at 63 FR 29620 (June 1, 1998) and 1211 OG 82 (June 23, 1998).
[2	2. This application does not contain, as a separate part of the disclosure on paper copy, a "Sequence Listing" as required by 37 C.F.R. 1.821(c).
[2	3. A copy of the "Sequence Listing" in computer readable form has not been submitted as required by 37 C.F.R. 1.821(e).
	4. A copy of the "Sequence Listing" in computer readable form has been submitted. However, the content of the computer readable form does not comply with the requirements of 37 C.F.R. 1.822 and/or 1.823, as indicated on the attached copy of the marked -up "Raw Sequence Listing."
	5. The computer readable form that has been filed with this application has been found to be damaged and/or unreadable as indicated on the attached CRF Diskette Problem Report. A Substitute computer readable form must be submitted as required by 37 C.F.R. 1.825(d).
	6. The paper copy of the "Sequence Listing" is not the same as the computer readable from of the "Sequence Listing" as required by 37 C.F.R. 1.821(e).
	7. Other:
A	pplicant Must Provide:
×	An initial or <u>substitute</u> computer readable form (CRF) copy of the "Sequence Listing".
×	An initial or <u>substitute</u> paper copy of the "Sequence Listing", as well as an amendment directing its entry into the specification.
×	A statement that the content of the paper and computer readable copies are the same and, where applicable, include no new matter, as required by 37 C.F.R. 1.821(e) or 1.821(f) or 1.821(g) or 1.825(b) or 1.825(d).
F	or questions regarding compliance to these requirements, please contact:
F	or Rules Interpretation, call (703) 308-4216 or CRF Submission Help, call (703) 308-4212 atentIn Software Program Support
	Technical Assistance703-287-0200

To Purchase Patentln Software......703-306-2600